(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer preferred paper session included a presentation by Dr. Thomas Powles discussing the first phase 2 results from the NORSE study assessing erdafitinib or erdafitinib plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma and fibroblast growth factor receptor (FGFR) alterations. First-line therapy for cisplatin-ineligible patients with metastatic urothelial carcinoma includes alternative chemotherapy or anti-PD-(L)1 monotherapy for PD-L1 positive tumors. Given that >50% of patients with metastatic urothelial carcinoma are ineligible for cisplatin treatment, there is a significant unmet need for new treatments for these particular patients.